1例EGFR野生型肺腺癌的靶向治疗
| 作者: |
1刘斌,
1黄彭,
1刘双柏,
1梁彦超,
1谢波
1 中南大学湘雅医学院附属株洲医院呼吸一科，湖南 株洲 412007 |
| 通讯: |
谢波
Email: potter0712@126.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.11.046 |
摘要
探讨EGFR野生型肺腺癌患者服用表皮生长因子受体酪氨酸激酶抑制剂(epithelial growth factor receptor-tyrosine kinase inhibitors，EGFR-TKIs)后的耐药机制。回顾性分析中南大学湘雅医学院附属株洲医院1例服用埃克替尼耐药后行EGFR T790M基因检测呈阳性的肺腺癌晚期患者的临床实践。该患者使用埃克替尼13个月后出现耐药，奥希替尼使用7个月后死亡，总生存期为22个月。对于肺腺癌患者，需常规行基因检测，一代TKI耐药后行T790M检测是必要的。
关键词：
非小细胞肺癌；表皮生长因子受体酪氨酸激酶抑制剂；T790M；奥希替尼
Targeted therapy for EGFR wild-type lung adenocarcinoma: A case report
CorrespondingAuthor: XIE Bo Email: potter0712@126.com
DOI: 10.3978/j.issn.2095-6959.2019.11.046
Abstract
This paper investigated the resistance mechanism in patients with EGFR wild-type lung adenocarcinoma treated with epithelial growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI). The clinical practice of a case of advanced lung adenocarcinoma with positive EGFR T790M gene test after taking icotinib resistance in our hospital was retrospectively analyzed. The patient developed resistance to icotinib 13 months after treatment, and died after 7 months on osimertinib, the overall survival was 22 months. For patients with lung adenocarcinoma, routine genetic testing is indispensable, and it is necessary to detect T790M after the first generation TKI drug resistance.
Keywords：
non-small cell lung cancer; epidermal growth factor receptor-tyrosine kinase inhibitor; T790M; osimertinib